ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 3, 2014
Teva Pharma: Underpriced and Misunderstood
The generics pharma giant remains one of our top ideas.
May 2, 2014
Valuentum's May Edition of Its Dividend Growth Newsletter!
The May edition of our Dividend Growth Newsletter is now available.
May 1, 2014
Highly-Rated Best Ideas Portfolio Holding DirecTV Catches a Bid
We continue to like DirecTV’s valuation, and the firm remains an acquisition target.
Apr 30, 2014
Earnings from 3 Internet Giants: eBay, Facebook, and Twitter
Assessing the contribution of equity value from each distinct period of Valuentum’s three-stage discounted cash flow model is a good way to assess underlying intrinsic-value uncertainty.
Apr 29, 2014
Earnings from 8 Interesting Ideas
Let’s examine the recent earnings reports from 8 firms that you should know about.
Apr 28, 2014
Pounding the Table on Apple's Shares...Again
Apple has been a huge contributor to the outperformance of the Best Ideas portfolio. If you haven't considered owning it, it may be time to take a look.
Apr 28, 2014
Dividend Increases for the Week Ending April 25
Let's take a look at dividend increases for the week ending April 25.
Apr 25, 2014
Baidu’s Internet Presence in China Is Phenomenal
We continue to like Baidu as a holding in the Best Ideas portfolio.
Apr 25, 2014
Earnings from 15 Dividend Growth Giants
Let’s take a look at recent results from a number of big dividend payers.
Apr 24, 2014
Apple Is Back!
We never thought the firm left, but the media seemed to think so. Let’s dig into the iPhone-maker’s fiscal second-quarter performance.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.